IR&MEDIA

NEWS

REV-MED Nears Entry into Brazil, Establishing a Strategic Gateway to the Latin American Market

관리자
7 Jun 2026
Views 224

2b6069aaa0124.png


Advanced regenerative medicine company REV-MED (CEO Edward BG Shin) is accelerating its expansion into the Brazilian biological products market, leveraging its advanced technologies and growing global presence.

Since designating 2025 as its “Year of Global Expansion,” REV-MED has rapidly broadened its international footprint across Europe, Asia, and now Latin America.

Most recently, the company participated in Hospitalar 2025, held in São Paulo, Brazil, further strengthening expectations for its expansion into Brazil and the broader Latin American market.

Hospitalar is the largest medical device exhibition in South America, attracting more than 1,200 companies and over 100,000 healthcare professionals from around the world this year.

At the event, REV-MED showcased its flagship platforms, TriCell and NovaStem, which utilize biological extraction technologies based on autologous blood and bone marrow. The technologies attracted significant attention from local healthcare professionals and industry stakeholders.

Brazil is the largest medical device market in Latin America, with an estimated market value of approximately USD 4.7 billion, ranking among the top ten medical device markets globally.

The regenerative medicine sector in South America is experiencing rapid growth, with Brazil recognized as one of the region’s most important markets.

According to global market research, the Latin American regenerative medicine market is projected to expand from USD 2.6 billion in 2024 to approximately USD 8.1 billion by 2029.

The PRP (Platelet-Rich Plasma) therapy market is also expected to grow significantly, increasing from USD 9.06 billion in 2024 to approximately USD 25 billion by 2032. Rising demand for minimally invasive procedures and chronic disease management is considered a key driver of this growth.

REV-MED has already demonstrated its technological competitiveness through regulatory approvals from major international authorities, including Japan’s PMDA and China’s NMPA.

In particular, approval from Japan’s Ministry of Health enabled the company to accelerate its expansion across Asia, while its products are currently exported to more than 30 countries throughout Europe, the Middle East, and other regions.

The company’s growing success in global markets is supported by strong confidence in its technologies and products.

To further strengthen credibility, REV-MED has published approximately 20 SCI(E)-indexed research papers and continues to engage in active academic collaborations and scientific research.

A REV-MED representative stated, “Through this exhibition, we have established an important gateway for expansion into the South American market and will continue strengthening our leadership position in the global regenerative medicine industry.”

The representative added, “Based on our proprietary technologies, we will continue expanding our global presence while delivering more advanced and innovative medical solutions.”

Meanwhile, REV-MED also plans to expand its domestic market share as Korea’s regenerative medicine sector becomes increasingly active following amendments to the Advanced Regenerative Medicine and Advanced Biopharmaceuticals Safety Act.

A company representative commented, “The amendment to the Advanced Regenerative Medicine Act represents an important turning point that creates new growth opportunities for Korea’s regenerative medicine market. We are fully prepared to lead this transformation.”

The representative concluded, “Based on our proprietary technologies and infrastructure, we will continue strengthening our competitiveness in the global biological products market and remain committed to providing innovative therapeutic solutions.”

Source: Daily Medi

0 0